Xilio Therapeutics (XLO)
(Delayed Data from NSDQ)
$0.78 USD
+0.05 (7.51%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $0.76 -0.02 (-2.56%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.78 USD
+0.05 (7.51%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $0.76 -0.02 (-2.56%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Zacks News
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
by Zacks Equity Research
Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.